Compare · APLT vs BTAI
APLT vs BTAI
Side-by-side comparison of Applied Therapeutics Inc. (APLT) and BioXcel Therapeutics Inc. (BTAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLT and BTAI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- APLT is the larger of the two at $70.8M, about 2.1x BTAI ($34.1M).
- BTAI has hit the wire 6 times in the past 4 weeks while APLT has been quiet.
- BTAI has more recent analyst coverage (12 ratings vs 11 for APLT).
- Company
- Applied Therapeutics Inc.
- BioXcel Therapeutics Inc.
- Price
- $0.11+5.91%
- $1.10+0.45%
- Market cap
- $70.8M
- $34.1M
- 1M return
- -
- -10.53%
- 1Y return
- -
- -43.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 0
- 6
- Recent ratings
- 11
- 12
Applied Therapeutics Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Latest APLT
- SEC Form 15-12G filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- SEC Form EFFECT filed by Applied Therapeutics Inc.
- Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Skyler Jay S returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Funtleyder Leslie D. was granted 1,187,500 shares and returned 2,375,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Bailey Evan Prescott returned 1,235,915 shares to the company and was granted 437,500 shares, closing all direct ownership in the company (SEC Form 4)
- Director Lerner Teena returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest BTAI
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
- Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)
- Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)
- Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)
- CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)
- SEC Form 144 filed by BioXcel Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results